ALPHARETTA, Ga.--(BUSINESS WIRE)--Carticept Medical, Inc., a developer of innovative products for the treatment of cartilage injuries and osteoarthritis, today announced that the first patient has been treated in an international, multi-center study of the Company’s Cartiva Synthetic Cartilage Implant (SCI). The study aims to determine the effectiveness of Cartiva SCI in comparison to arthrodesis (joint fusion), the current standard of care, for reducing the debilitating pain associated with osteoarthritis of the first metatarsophalangeal (MTP) joint.
